Advances and Novel Treatment Options in Metastatic Melanoma
The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field.
שמור ב:
| מחברים אחרים: | , , |
|---|---|
| פורמט: | Book Chapter |
| יצא לאור: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| נושאים: | |
| גישה מקוונת: | Get Fullteks DOAB: description of the publication |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
| LEADER | 04842naaaa2201657uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_79644 | ||
| 005 | 20220321 | ||
| 020 | |a books978-3-0365-3303-2 | ||
| 020 | |a 9783036533049 | ||
| 020 | |a 9783036533032 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-3303-2 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Facchiano, Antonio |4 edt | |
| 700 | 1 | |a Del Bufalo, Donatella |4 edt | |
| 700 | 1 | |a Carè, Alessandra |4 edt | |
| 700 | 1 | |a Facchiano, Antonio |4 oth | |
| 700 | 1 | |a Del Bufalo, Donatella |4 oth | |
| 700 | 1 | |a Carè, Alessandra |4 oth | |
| 245 | 1 | 0 | |a Advances and Novel Treatment Options in Metastatic Melanoma |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (528 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a melanoma | ||
| 653 | |a invasion | ||
| 653 | |a WNT5A | ||
| 653 | |a MARCKS | ||
| 653 | |a phosphorylation | ||
| 653 | |a MANS peptide | ||
| 653 | |a nanoparticles | ||
| 653 | |a cell therapy | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a sex/gender | ||
| 653 | |a sex-hormones | ||
| 653 | |a immunity | ||
| 653 | |a microRNAs | ||
| 653 | |a immunotherapy | ||
| 653 | |a BRAF-mutant melanoma | ||
| 653 | |a BRAF inhibitor | ||
| 653 | |a mechanism of action | ||
| 653 | |a targeted therapy | ||
| 653 | |a tumour microenvironment | ||
| 653 | |a plasmacytoid dendritic cells | ||
| 653 | |a lactate dehydrogenase | ||
| 653 | |a TLR | ||
| 653 | |a interferon | ||
| 653 | |a CXCL10 | ||
| 653 | |a TPC2 | ||
| 653 | |a HIPPO | ||
| 653 | |a SOCE | ||
| 653 | |a metastasis | ||
| 653 | |a essential oils | ||
| 653 | |a angiogenesis | ||
| 653 | |a apoptosis | ||
| 653 | |a uveal melanoma (UM) | ||
| 653 | |a metastatic uveal melanoma (mUM) | ||
| 653 | |a prognostication | ||
| 653 | |a adjuvant therapy | ||
| 653 | |a metastatic therapy | ||
| 653 | |a metastatic dormancy | ||
| 653 | |a liver-directed-therapies | ||
| 653 | |a targeted-therapy | ||
| 653 | |a combined therapy | ||
| 653 | |a protein tyrosine phosphatase | ||
| 653 | |a PTPs inhibitors | ||
| 653 | |a melanoma immune infiltrate | ||
| 653 | |a BRAF inhibitors | ||
| 653 | |a microenvironment | ||
| 653 | |a resistance | ||
| 653 | |a therapy | ||
| 653 | |a therapeutic resistance | ||
| 653 | |a exosomes | ||
| 653 | |a extracellular vesicles | ||
| 653 | |a diagnosis | ||
| 653 | |a prognosis | ||
| 653 | |a ctDNA | ||
| 653 | |a liquid biopsy | ||
| 653 | |a prediction | ||
| 653 | |a patient stratification | ||
| 653 | |a BRAF | ||
| 653 | |a arthralgia | ||
| 653 | |a rheumatoid arthritis | ||
| 653 | |a carbonic anhydrase | ||
| 653 | |a hedgehog | ||
| 653 | |a cyclopamine | ||
| 653 | |a small molecules | ||
| 653 | |a acetazolamide | ||
| 653 | |a motility | ||
| 653 | |a metalloproteinases | ||
| 653 | |a FAK | ||
| 653 | |a cancer | ||
| 653 | |a mucosal melanoma | ||
| 653 | |a nivolumab | ||
| 653 | |a pembrolizumab | ||
| 653 | |a ipilimumab | ||
| 653 | |a radiotherapy | ||
| 653 | |a cholinergic system | ||
| 653 | |a acetylcholine | ||
| 653 | |a muscarinic receptors | ||
| 653 | |a nicotinic receptors | ||
| 653 | |a melanoma metastasis | ||
| 653 | |a ShcD adaptor protein | ||
| 653 | |a amoeboid motility | ||
| 653 | |a Rac1 | ||
| 653 | |a DOCK4 | ||
| 653 | |a melanoma PDX | ||
| 653 | |a target therapy | ||
| 653 | |a cancer stem cells | ||
| 653 | |a slow cycling phenotype | ||
| 653 | |a drug resistance | ||
| 653 | |a OXPHOS | ||
| 653 | |a lipid metabolism | ||
| 653 | |a cancer associated fibroblast | ||
| 653 | |a melanomagenesis | ||
| 653 | |a biomarkers | ||
| 653 | |a checkpoint inhibitor | ||
| 653 | |a PD-1 | ||
| 653 | |a melanoma markers | ||
| 653 | |a cytokines | ||
| 653 | |a machine learning | ||
| 653 | |a Support Vector Machine | ||
| 653 | |a principal component analysis | ||
| 653 | |a BCL2L10 | ||
| 653 | |a STAT3 | ||
| 653 | |a cytotoxicity | ||
| 653 | |a survival | ||
| 653 | |a ABT-737 | ||
| 653 | |a Bcl-2 family | ||
| 653 | |a ML258 | ||
| 653 | |a HuR | ||
| 653 | |a MITF | ||
| 653 | |a metastases | ||
| 653 | |a siRNA | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5029 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/79644 |7 0 |z DOAB: description of the publication |